This segment focuses on the discovery, development, and clinical evaluation of novel cancer therapies, with a primary emphasis on precision oncology. Research and development activities include target identification, drug candidate selection, preclinical studies, and clinical trials. Tango Therapeutics utilizes synthetic lethality and other innovative approaches to identify and validate drug targets in genetically defined patient populations. The company's technology platforms include small molecule inhibitors and potentially other modalities. The therapeutic areas of focus are cancers with MTAP deletions and BRCA1 mutations, among others. The goal is to improve patient outcomes by developing targeted therapies that address the underlying genetic drivers of cancer. Market positioning is based on a focus on precision medicine and strategic collaborations with industry leaders like Gilead Sciences. Future opportunities include expanding the pipeline and advancing clinical programs. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships with Gilead Sciences support the development and commercialization of therapies.